Key result
This editorial discusses the phase 2 INSIGNIA-PAH trial evaluating the efficacy and safety of MK-5475, an inhaled soluble guanylate cyclase stimulator, for pulmonary arterial hypertension.
This editorial highlights the potential of inhaled therapies like MK-5475 to provide direct lung delivery with fewer systemic side effects in the treatment of pulmonary arterial hypertension.
Extract The treatment landscape of pulmonary arterial hypertension (PAH) continues to evolve rapidly with the recent international approval of sotatercept in the USA for treatment of adults with PAH. Sotatercept is a fusion protein that traps activins and growth differentiation factors, which has potential anti-remodelling properties on the pulmonary vasculature relevant to PAH pathogenesis. Concerns over systemic side-effects of PAH therapies have increased efforts towards more direct lung delivery of treatments via the inhalational route. This approach may be more favourable mechanistically by allowing for a lower administered dose direct to the pulmonary mucosa with less systemic absorption. Inhaled PAH therapies may also be more patient-friendly if accompanied by an acceptable administration schedule and side-effect profile. To this end, the phase 2 INSIGNIA-PAH trial, reported in this month's issue of the European Respiratory Journal, is a dose-finding study evaluating the efficacy of MK-5475, an inhaled soluble guanylate cyclase (sGC) stimulator, for the treatment of PAH with emphasis on the drug's safety and systemic side-effect profile [1].
No takes yet. Share an insight, caveat, or question.
McCabe et al. (2024) conducted an editorial in Pulmonary arterial hypertension. MK-5475 was evaluated. This editorial discusses the phase 2 INSIGNIA-PAH trial evaluating the efficacy and safety of MK-5475, an inhaled soluble guanylate cyclase stimulator, for pulmonary arterial hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: